SUPERNUS PHARMACEUTICALS INC's ticker is and the CUSIP is 868459AD0. A total of 47 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $294,910 | -87.0% | 303,000 | -86.9% | 0.00% | -89.5% |
| Q2 2022 | $2,260,576 | -81.7% | 2,319,000 | -81.5% | 0.02% | -75.6% |
| Q1 2022 | $12,364,012 | -2.3% | 12,523,000 | -1.7% | 0.08% | +5.4% |
| Q4 2021 | $12,658,285 | +24.4% | 12,740,000 | +23.6% | 0.07% | 0.0% |
| Q3 2021 | $10,175,027 | -17.9% | 10,308,000 | -17.4% | 0.07% | -5.1% |
| Q2 2021 | $12,398,079 | +30.6% | 12,485,000 | +28.0% | 0.08% | -6.0% |
| Q1 2021 | $9,496,635 | +127.9% | 9,754,000 | +123.2% | 0.08% | +151.5% |
| Q4 2020 | $4,167,638 | +8405.4% | 4,371,000 | +8147.2% | 0.03% | +3200.0% |
| Q3 2020 | $49,000 | -99.3% | 53,000 | -99.3% | 0.00% | -98.8% |
| Q2 2020 | $6,879,000 | -4.9% | 7,749,000 | -12.6% | 0.08% | +1.2% |
| Q1 2020 | $7,230,000 | -4.7% | 8,867,000 | +6.4% | 0.08% | +35.6% |
| Q4 2019 | $7,588,000 | +2068.0% | 8,330,000 | +2220.3% | 0.06% | +1866.7% |
| Q2 2019 | $350,000 | – | 359,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 71,162 | $69,799,000 | 4.72% |
| ZAZOVE ASSOCIATES LLC | 27,692,000 | $27,021,000 | 2.38% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 61,727,000 | $60,252,000 | 1.17% |
| SHENKMAN CAPITAL MANAGEMENT INC | 7,637,000 | $7,524,000 | 0.85% |
| NN Investment Partners Holdings N.V. | 38,700,000 | $37,743,000 | 0.30% |
| CAMDEN ASSET MANAGEMENT L P /CA | 5,825,000 | $5,684,000 | 0.18% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 4,479,000 | $4,384,000 | 0.16% |
| Lombard Odier Asset Management (Europe) Ltd | 2,005,000 | $1,905,000 | 0.16% |
| PRUDENTIAL PLC | 41,809,000 | $40,973,000 | 0.12% |
| Calamos Advisors LLC | 22,303,000 | $21,829,000 | 0.12% |